Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  1. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Clonotypic Diversity of the T-cell Receptor Corroborates the Immature Precursor Origin of Cutaneous T-cell Lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Triage May Improve Selection to Colonoscopy and Reduce the Number of Unnecessary Colonoscopies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Elevated serum levels of biochemical markers of bone turnover and YKL-40 in patients with metastatic prostate cancer (PC) at the time of diagnosis are associated to poor prognosis. In this study, we evaluated the value of these biomarkers in monitoring the patients during hormonal treatment.
OriginalsprogEngelsk
TidsskriftClinical Cancer Research
Vol/bind13
Udgave nummer11
Sider (fra-til)3244-9
Antal sider6
ISSN1078-0432
DOI
StatusUdgivet - 1 jun. 2007

ID: 31004104